Pure Global
NCT06373406

A Study of MHB036C for Advanced Solid Tumor

A Phase I/II, Dose Escalation and Dose Expansion Study of MHB036C for Advanced Solid Tumor to Evaluate the Tolerability/Safety, Pharmacokinetics and Efficacy
Minghui Pharmaceutical (Hangzhou) Ltd·Phase 1/2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
MHB036C
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 1/2
Start date
May 18, 2023
End date
Dec 01, 2024
Enrollment
200 participants
Primary outcome

Incidence of participants with adverse events (AE),Number of participants with dose-limiting toxicity (DLT)

Summary

Phase I/II, dose escalation and dose expansion study to evaluate the efficacy and safety of
 MHB036C in advanced malignant tumors.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06373406
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06373406 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Minghui Pharmaceutical (Hangzhou) Ltd and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.